Please Scroll Down to See Forums Below 
Contains 30 ug ethinyl estradiol and 3.0 mg drospirenone.
From their website.
YASMIN contains 3 mg of the new progestin drospirenone. Drospirenone is a spironolactone analogue, and the drospirenone in YASMIN has AntiMineralocorticoid activity equivalent to 25 mg of spironolactone. Because of this activity, YASMIN affects the sodium and water balance. Like spironolactone, YASMIN should not be used in certain women with renal, hepatic, or adrenal problems that could predispose to hyperkalemia. And, like spironolactone, women receiving daily, long-term treatment for chronic conditions or diseases with medications that may increase serum potassium should have their serum potassium level checked during the first treatment cycle.†
Drospirnone provides an AntiMineralocorticoid effect
Ethinyl estradiol, the estrogen found in today’s combination OCs, can increase the amount of angiotensinogen produced by the liver, inducing renin activity and the accompanying aldosterone release. When aldosterone activates its receptors, the kidneys reabsorb sodium and water. Drospirenone blocks aldosterone receptors in the kidney, counteracting the effect of increased aldosterone levels caused by ethinyl estradiol. While drospirenone increases sodium and water excretion, it does not promote potassium loss.
Drospirenone provides an AntiAndrogenic* effect
Unlike other progestins available in the US, drospirenone blocks the action of androgens by acting as an antagonist at the androgen receptors. In addition, drospirenone does not counteract sex hormone-binding globulin (SHBG) synthesis. Further, it does not prevent SHBG-testosterone binding, leaving less free testosterone to bind with androgen receptors. Finally, it inhibits production of ovarian androgens.
Clinically proven benefits of Yasmin®
YASMIN works like other combination OCs to prevent pregnancy by suppressing gonadotropins, inhibiting ovulation, and inducing changes in the cervical mucus and endometrium. With a corrected Pearl Index of 0.55, YASMIN is more than 99% effective — just as effective as other OCs. YASMIN provides excellent cycle control, with a low incidence of breakthrough bleeding and spotting. Overall, occurrences of breakthrough bleeding and spotting decreased significantly after the first 3 cycles.
Worldwide experience
YASMIN is today's fastest growing OC and has been prescribed to more than one million women worldwide. In both the US and European clinical trials, a total of 2629 patients received YASMIN tablets — with contraceptive efficacy assessed in 33,160 total cycles.
Proven tolerability profile
In clinical trials, YASMIN was shown to have a low incidence of adverse events that are typical of those associated with OC use. Blood pressure, lipids, glucose, electrolytes, and hematology values stayed within normal ranges in the majority of women in clinical trials.
YASMIN is contraindicated in patients with renal insufficiency, hepatic dysfunction, or adrenal insufficiency.
OCs do not protect against HIV infection and other sexually transmitted diseases. The use of OCs is associated with increased risks of several serious side effects. Cigarette smoking increases the risk of serious cardiovascular side effects; women who take OCs are strongly advised not to smoke.
*AntiAndrogenic activity seen in preclinical studies.
†Drugs that may increase serum potassium when taken daily and long-term for chronic conditions include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, heparin, aldosterone antagonists, and NSAIDs.
From their website.
YASMIN contains 3 mg of the new progestin drospirenone. Drospirenone is a spironolactone analogue, and the drospirenone in YASMIN has AntiMineralocorticoid activity equivalent to 25 mg of spironolactone. Because of this activity, YASMIN affects the sodium and water balance. Like spironolactone, YASMIN should not be used in certain women with renal, hepatic, or adrenal problems that could predispose to hyperkalemia. And, like spironolactone, women receiving daily, long-term treatment for chronic conditions or diseases with medications that may increase serum potassium should have their serum potassium level checked during the first treatment cycle.†
Drospirnone provides an AntiMineralocorticoid effect
Ethinyl estradiol, the estrogen found in today’s combination OCs, can increase the amount of angiotensinogen produced by the liver, inducing renin activity and the accompanying aldosterone release. When aldosterone activates its receptors, the kidneys reabsorb sodium and water. Drospirenone blocks aldosterone receptors in the kidney, counteracting the effect of increased aldosterone levels caused by ethinyl estradiol. While drospirenone increases sodium and water excretion, it does not promote potassium loss.
Drospirenone provides an AntiAndrogenic* effect
Unlike other progestins available in the US, drospirenone blocks the action of androgens by acting as an antagonist at the androgen receptors. In addition, drospirenone does not counteract sex hormone-binding globulin (SHBG) synthesis. Further, it does not prevent SHBG-testosterone binding, leaving less free testosterone to bind with androgen receptors. Finally, it inhibits production of ovarian androgens.
Clinically proven benefits of Yasmin®
YASMIN works like other combination OCs to prevent pregnancy by suppressing gonadotropins, inhibiting ovulation, and inducing changes in the cervical mucus and endometrium. With a corrected Pearl Index of 0.55, YASMIN is more than 99% effective — just as effective as other OCs. YASMIN provides excellent cycle control, with a low incidence of breakthrough bleeding and spotting. Overall, occurrences of breakthrough bleeding and spotting decreased significantly after the first 3 cycles.
Worldwide experience
YASMIN is today's fastest growing OC and has been prescribed to more than one million women worldwide. In both the US and European clinical trials, a total of 2629 patients received YASMIN tablets — with contraceptive efficacy assessed in 33,160 total cycles.
Proven tolerability profile
In clinical trials, YASMIN was shown to have a low incidence of adverse events that are typical of those associated with OC use. Blood pressure, lipids, glucose, electrolytes, and hematology values stayed within normal ranges in the majority of women in clinical trials.
YASMIN is contraindicated in patients with renal insufficiency, hepatic dysfunction, or adrenal insufficiency.
OCs do not protect against HIV infection and other sexually transmitted diseases. The use of OCs is associated with increased risks of several serious side effects. Cigarette smoking increases the risk of serious cardiovascular side effects; women who take OCs are strongly advised not to smoke.
*AntiAndrogenic activity seen in preclinical studies.
†Drugs that may increase serum potassium when taken daily and long-term for chronic conditions include ACE inhibitors, angiotensin-II receptor antagonists, potassium-sparing diuretics, heparin, aldosterone antagonists, and NSAIDs.
